ArticleNeurologia medico-chirurgica2026
Prognostic Impact of Clinical Diagnosis-based Treatment in Glioblastoma Patients Aged ≥80 Years: A Single-center Cohort Study Focused on Performance Status Maintenance.
Article in Neurologia medico-chirurgica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Beyond Chronological Age: A Scoping Review of Neurosurgical Intervention for Central Nervous System Tumors in the Very Elderly.Current oncology (Toronto, Ont.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In aging societies such as Japan, the number of patients aged ≥80 years with glioblastoma who are unsuited for surgery is rapidly increasing. At our institution, we adopted a therapeutic strategy based on clinical diagnosis without histological confirmation when surgery was not feasible. This study aimed to retrospectively evaluate the short-term outcomes and clinical value of surgical intervention and histological confirmation in this population. Patients aged ≥80 years diagnosed with glioblastoma between 2011 and 2025 were reviewed. Clinical diagnosis was applied when patients were unfit for surgery. Patient data, including age, sex, Karnofsky performance status, extent of resection, treatment options, and complications, were analyzed for associations with overall survival, Karnofsky performance status improvement, and discharge home. Among 203 cases, 31 patients (15.3%) were included. Their mean age was 84 years; the median Karnofsky performance status scores at admission and discharge were 50 and 60, respectively. Six patients underwent resection, 14 biopsy, and 11 clinical diagnosis. The clinical diagnosis group showed better functional outcomes, including improved Karnofsky performance status, shorter hospitalization, and higher discharge home rates than the biopsy group. Bevacizumab contributed significantly to these outcomes. Perioperative complications occurred in 4 patients; none recovered functionally or were discharged home. Low Karnofsky performance status at discharge was the only independent predictor of poor overall survival. Surgical intervention did not significantly affect the functional and survival outcomes. In conclusion, clinical diagnosis-based treatment, particularly with bevacizumab, could help preserve function and facilitate discharge in very elderly patients with glioblastoma. Biopsies might negatively impact the outcomes in the present cohort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.